Literature DB >> 22841588

Efficacy but side effects of anakinra therapy for chronic refractory gout in a renal transplant recipient with preterminal chronic renal failure.

Guillaume Direz, Natacha Noël, Charlotte Guyot, Olivier Toupance, Jean-Hugues Salmon, Jean-Paul Eschard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22841588     DOI： 10.1016/j.jbspin.2012.04.009

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


× No keyword cloud information.
  6 in total

Review 1.  The Future of IL-1 Targeting in Kidney Disease.

Authors:  Baris Afsar; Adrian Covic; Alberto Ortiz; Rengin Elsurer Afsar; Mehmet Kanbay
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 2.  Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations.

Authors:  Peleg Rider; Yaron Carmi; Idan Cohen
Journal:  Int J Cell Biol       Date:  2016-12-19

3.  Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocol study.

Authors:  Gowrie Balasubramaniam; Trisha Parker; David Turner; Mike Parker; Jonathan Scales; Patrick Harnett; Michael Harrison; Khalid Ahmed; Sweta Bhagat; Thiraupathy Marianayagam; Costantino Pitzalis; Christian Mallen; Edward Roddy; Mike Almond; Bhaskar Dasgupta
Journal:  BMJ Open       Date:  2017-09-05       Impact factor: 2.692

4.  Peri- and Postoperative Treatment with the Interleukin-1 Receptor Antagonist Anakinra Is Safe in Patients Undergoing Renal Transplantation: Case Series and Review of the Literature.

Authors:  Catharina M Mulders-Manders; Marije C Baas; Femke M Molenaar; Anna Simon
Journal:  Front Pharmacol       Date:  2017-05-31       Impact factor: 5.810

Review 5.  Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review.

Authors:  Huai Leng Pisaniello; Mark C Fisher; Hamish Farquhar; Ana Beatriz Vargas-Santos; Catherine L Hill; Lisa K Stamp; Angelo L Gaffo
Journal:  Arthritis Res Ther       Date:  2021-04-28       Impact factor: 5.156

Review 6.  The emerging role of biotechnological drugs in the treatment of gout.

Authors:  L Cavagna; W J Taylor
Journal:  Biomed Res Int       Date:  2014-04-16       Impact factor: 3.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.